Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 6.22% | 2.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.22% | 2.74% | |||
| Cost of Revenue | 8.53% | 28.83% | |||
| Gross Profit | 3.83% | -15.06% | |||
| SG&A Expenses | -26.81% | 12.18% | |||
| Depreciation & Amortization | -17.53% | -34.70% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.65% | 8.45% | |||
| Operating Income | 28.90% | -17.31% | |||
| Income Before Tax | 33.52% | 34.10% | |||
| Income Tax Expenses | 112.02% | 65.32% | |||
| Earnings from Continuing Operations | 27.75% | 29.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.75% | 29.43% | |||
| EBIT | 28.90% | -17.31% | |||
| EBITDA | 14.43% | -17.12% | |||
| EPS Basic | 27.74% | 29.48% | |||
| Normalized Basic EPS | 33.52% | -24.09% | |||
| EPS Diluted | 27.74% | 29.48% | |||
| Normalized Diluted EPS | 33.52% | -24.09% | |||
| Average Basic Shares Outstanding | 0.00% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||